Project Grant R21AI180181

Award Date 5/17/24
Completion Date 3/31/26
Dollars Obligated $871K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This Project Grant award of $799,354 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to comprehensively understand and pharmacologically target the necroptotic pathways in both the donor and recipient lungs to reduce the incidence of primary graft dysfunction (PGD) in lung transplantation. The research has two specific aims: 1) Exploring the role of TNF-α-induced autocrine necroptosis in monocyte-derived alveolar...
This $412,500 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research at the University of South Florida (USF) to study the molecular mechanisms of cell death pathways and develop small molecule inhibitors for treating diseases associated with dysregulated cell death, including systemic inflammatory response syndrome (SIRS), infection, and heart failure. The three-part research project...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to investigate the molecular mechanisms regulating neutrophil proinflammatory activity in sepsis. The $479,249 award will fund a study to determine how neutrophil signaling through the A20 protein contributes to organ damage and vaso-occlusive events in sepsis. The research will employ biochemical, cell...
This National Science Foundation (NSF) award under the Biological Sciences program (CFDA 47.074) provides $179,410 to the University of Central Florida Board of Trustees Office of Research to conduct research aimed at understanding the molecular basis for NOD2-dependent lipid mediator production. The 5-year project will: (1) determine if endogenous stimulation of NOD2 leads to RIP2-dependent phosphorylation and activation of 5-lipoxygenase; (2) identify the molecular features of RIP2 important...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $492,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct systematic genetic research on the mechanisms governing immunogenic cell death (ICD). The research aims to decipher the signaling pathways and molecular processes that regulate the immune system's ability to recognize...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,258,391 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Massachusetts Medical School to conduct research on the RNA splicing factor RAVER1 and its role in regulating cell death, inflammation, and innate immunity. The research aims to elucidate how RAVER1 and the related splicing factor PTBP1 control the splicing, expression, and function of the RIPK1 kinase, which serves...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to elucidate the innate and adaptive immune mechanisms governing neonatal immune responses and sterile inflammation. The $797,735 award will support a 5-year research project that utilizes a novel mouse model to investigate heightened early-life immune system reactivity that may underlie the propensity for inflammatory...
This $1,675,000 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support a 5-year research project at the University of Massachusetts Medical School (UMass Medical) to study the mechanisms that regulate different forms of regulated cell death, including apoptosis and various types of regulated necrosis. The research aims to gain a deeper mechanistic understanding of how different...
This $462,000 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate how the human microbiome regulates neutrophil immune responses and impacts sepsis outcomes. The key objectives are to: Elucidate the mechanism by which the microbiome "primes" or trains human neutrophils during homeostasis, leading to differential inflammatory responses....
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) totaling $373,375 will support research to understand the interactions between ultra-small nanoparticles (USNPs) and inflammatory monocytes, and how these interactions can be leveraged to target inflammation. The research aims to: 1) determine the fundamental mechanisms governing USNP-inflammatory monocyte interactions, including how the USNP...

INNATE IMMUNE RECEPTOR DRIVEN PROGRAMMED NECROSIS IS COUPLED TO HYPER-SYNTHESIS OF INFLAMMATORY LIPID MEDIATORS IN HOST DEFENSE - PROJECT SUMMARY INFLAMMATORY RESPONSES ORGANIZED BY INNATE IMMUNE CELLS ARE CRITICAL TO DEFEND AGAINST INFECTIOUS INSULT AND INITIATE HEALING RESPONSES TO INJURY. MECHANISMS THAT TETHER THE STRENGTH OF THE INFLAMMATORY RESPONSE TO THE MAGNITUDE OF THE THREAT ARE EQUALLY IMPORTANT TO LIMIT UNNECESSARILY DAMAGING ASPECTS OF THE INNATE IMMUNE RESPONSE. INFLAMMATORY MODES OF PROGRAMMED CELL DEATH SUCH AS NECROPTOSIS ARE A CRITICAL LAST LINE OF CELL INTRINSIC DEFENSE TO REMOVE INFECTED AND IRREPARABLE CELLS WHILE SIMULTANEOUSLY CREATING AND EXPANDING AN INFLAMMATORY STATE IN REMAINING HEALTHY TISSUES. HOW INFLAMMATORY MODES OF DEATH SUCH AS NECROPTOSIS CREATE INFLAMMATION IS IMPORTANT TO UNDERSTAND AS IT NOT ONLY PROVIDES INSIGHT INTO THE ROLES OF NECROPTOSIS IN DEFENSE AGAINST SPECIFIC PATHOGENS, BUT ALSO HELPS TO IDENTIFY THERAPEUTIC TARGETS THAT CAN BE PHARMACEUTICALLY LEVERAGED TO INHIBIT OUT OF CONTROL INFLAMMATION IN DISEASE STATES TYPIFIED BY UNREGULATED NECROPTOTIC DEATH. WE HAVE IDENTIFIED A NEW REGULATORY CIRCUIT BY WHICH THE NECROPTOTIC CELL DEATH PATHWAY IS COUPLED TO THE HYPERPRODUCTION AND RELEASE OF INFLAMMATORY LIPID MEDIATORS. THE ACTIVE SYNTHESIS OF INFLAMMATORY LIPIDS DURING NECROPTOTIC DEATH CRITICALLY REQUIRES THE ACTIVITY OF RIP KINASE 3 AND MAY IMPINGE UPON SPECIFIC PHOSPHO- LIPASES. WE HYPOTHESIZE THAT THIS LINKAGE OF CELL DEATH AND LIPID METABOLISM CAN SIGNIFICANTLY SHAPE INFLAMMATORY RESPONSES IN VITRO AND IN VIVO. IN AIM 1 WE WILL DEFINE THE MECHANISM BY WHICH CANONICAL NECROPTOTIC SIGNALS GOVERN HYPER-LIPID PRODUCTION IN PRIMARY IMMUNE CELLS. IN AIM2 WE WILL EXPLORE THE IMPLICATIONS OF THIS PHENOMENA FOR NECROPTOSIS ASSOCIATED INFLAMMATION.

Posted 5/17/24, 12:00 AM